Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Therapeutic and diagnostic implications of Hsp90 activation.
Kamal A, Boehm MF, Burrows FJ. Kamal A, et al. Among authors: burrows fj. Trends Mol Med. 2004 Jun;10(6):283-90. doi: 10.1016/j.molmed.2004.04.006. Trends Mol Med. 2004. PMID: 15177193 Free PMC article. Review.
Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D. Saif MW, et al. Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6. Cancer Chemother Pharmacol. 2013. PMID: 23564374 Clinical Trial.
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF. Kasibhatla SR, et al. Among authors: burrows fj. J Med Chem. 2007 Jun 14;50(12):2767-78. doi: 10.1021/jm050752+. Epub 2007 May 8. J Med Chem. 2007. PMID: 17488003
7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
Zhang L, Fan J, Vu K, Hong K, Le Brazidec JY, Shi J, Biamonte M, Busch DJ, Lough RE, Grecko R, Ran Y, Sensintaffar JL, Kamal A, Lundgren K, Burrows FJ, Mansfield R, Timony GA, Ulm EH, Kasibhatla SR, Boehm MF. Zhang L, et al. Among authors: burrows fj. J Med Chem. 2006 Aug 24;49(17):5352-62. doi: 10.1021/jm051146h. J Med Chem. 2006. PMID: 16913725
Orally active purine-based inhibitors of the heat shock protein 90.
Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR. Biamonte MA, et al. Among authors: burrows fj. J Med Chem. 2006 Jan 26;49(2):817-28. doi: 10.1021/jm0503087. J Med Chem. 2006. PMID: 16420067
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC, McKenzie A, Friedman J, Scannevin R, Kamal A, Hong K, Kasibhatla SR, Boehm MF, Burrows FJ. Lundgren K, et al. Among authors: burrows fj. Mol Cancer Ther. 2009 Apr;8(4):921-9. doi: 10.1158/1535-7163.MCT-08-0758. Mol Cancer Ther. 2009. PMID: 19372565
36 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page